Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The therapeutic promise of induced pluripotent stem cells (iPSCs) has spurred efforts to circumvent genome alteration when reprogramming somatic cells to pluripotency. Approaches based on episomal DNA, Sendai virus, and messenger RNA (mRNA) can generate "footprint-free" iPSCs with efficiencies equaling or surpassing those attained with integrating viral vectors. The mRNA method uniquely affords unprecedented control over reprogramming factor (RF) expression while obviating a cleanup phase to purge residual traces of vector. Currently, mRNA-based reprogramming is relatively laborious due to the need to transfect daily for ~2 weeks to induce pluripotency, and requires the use of feeder cells that add complexity and variability to the procedure while introducing a route for contamination with non-human-derived biological material. We accelerated the mRNA reprogramming process through stepwise optimization of the RF cocktail and leveraged these kinetic gains to establish a feeder-free, xeno-free protocol which slashes the time, cost and effort involved in iPSC derivation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other words, it cannot be applied successfully to cells that are inherently grown in suspension (such as blood cells) due to the negative impact of multiple rounds of transfections on cell viability.”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“mRNA reprogramming is usually applied only to cells that can survive multiple rounds of transfections, such as adherent cells (i.e., fibroblasts).”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications
Freshney, R. I. (2010) · Wiley eBooks · doi:10.1002/9780470649367 · Cited by 3,870
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Self-citationHuman induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008) · Science · doi:10.1126/science.1164270 · Cited by 2,009
Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells
Woltjen, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., Hämäläinen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009) · Nature · doi:10.1038/nature07863 · Cited by 1,814
Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins
Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.04.005 · Cited by 1,788
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Cited by
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Self-citationA comparison of non-integrating reprogramming methods
Schlaeger, T. M., Daheron, L., Brickler, T. R., Entwisle, S., Chan, K., Cianci, A., DeVine, A., Ettenger, A., Fitzgerald, K., Godfrey, M., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3070 · Cited by 510
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications
Doss, M. X., & Sachinidis, A. (2019) · Cells · doi:10.3390/cells8050403 · Cited by 456
Liu, L., Wang, Y., Miao, L., Liu, Q., Musetti, S., Li, J., & Huang, L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.020 · Cited by 373
Efficient generation of human iPSCs by a synthetic self-replicative RNA
Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312
Paull, D., Sevilla, A., Zhou, H., Hahn, A. K., Kim, H., Napolitano, C., Tsankov, A., Shang, L., Krumholz, K., Jagadeesan, P., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3507 · Cited by 263
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
“In 2010, mRNAs coding for the Yamanaka stem cell factors (Oct3/4, Sox2, Klf4, c-Myc) [165] containing pseudouridine and 5-methylcytydine were used to efficiently reprogram cells to pluripotency (iPS cells) without any integration events [166].”
MethodReprogramming human fibroblasts to pluripotency using modified mRNA
Mandal, P. K., & Rossi, D. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.019 · Cited by 221
Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells
Feng, Q., Shabrani, N., Thon, J. N., Huo, H., Thiel, A., Machlus, K. R., Kim, K., Brooks, J., Li, F., Luo, C., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.09.010 · Cited by 220
“The human iPSC line HA1-iPS was reprogrammed by mRNA (Warren et al., 2012) and obtained from Allele Biotechnology.”
MethodOmole, A. E., & Fakoya, A. O. J. (2018) · PeerJ · doi:10.7717/peerj.4370 · Cited by 204
Generating a Non-Integrating Human Induced Pluripotent Stem Cell Bank from Urine-Derived Cells
Xue, Y., Cai, X., Wang, L., Liao, B., Zhang, H., Shan, Y., Chen, Q., Zhou, T., Li, X., Hou, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070573 · Cited by 183
“To date, several non-viral approaches had been reported to generate mouse and human iPS cells, by using adeno-virus [6], plasmids [7], purified proteins [8,9], synthesized mRNA [10,11,12].”
BackgroundHigh-efficiency RNA-based reprogramming of human primary fibroblasts
Kogut, I., McCarthy, S. M., Pavlova, M., Astling, D. P., Chen, X., Jakimenko, A., Jones, K. L., Getahun, A., Cambier, J. C., Pasmooij, A. M. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03190-3 · Cited by 166
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
“as adjuvant therapy to modified mRNA delivery during these reprogramming studies [152,153,156].”
BackgroundFunction of human pluripotent stem cell-derived photoreceptor progenitors in blind mice
Barnea-Cramer, A. O., Wang, W., Lu, S.-J., Singh, M. S., Luo, C., Huo, H., McClements, M. E., Barnard, A. R., MacLaren, R. E., & Lanza, R. (2016) · Scientific Reports · doi:10.1038/srep29784 · Cited by 151
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Biomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
Xue, M., Zhao, R., Lin, H., & Jackson, C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.002 · Cited by 130
Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases
Trepotec, Z., Lichtenegger, E., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.012 · Cited by 115
Technological Overview of iPS Induction from Human Adult Somatic Cells
Bayart, E., & Cohen-Haguenauer, O. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020002 · Cited by 113
“The reprogramming efficiency achieved with this strategy is higher than with any other system, when addressing a range of human somatic donor cells under test [96, 97] and this approach is commercially available.”
Choi, H. Y., Lee, T., Yang, G., Oh, J., Won, J., Han, J., Jeong, G., Kim, J., Kim, J., Kim, B., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.007 · Cited by 120
Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112
Shao, Z., Noh, H., Kim, W. B., Ni, P., Nguyen, C. L., Cote, S. E., Noyes, E. A., Zhao, J., Parsons, T. J., Park, J. M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0313-z · Cited by 124
“…we chose patients who required clozapine treatment to narrow down the patient group to those with more severe cases of the disease (Figure 1a). iPSCs reprogrammed with modified RNA transfection 16 showed human pluripotent stem cell (hPSC)-like morphology and expressed hPSC markers (Figure 1b).”
InfluentialCieślar‐Pobuda, A., Knoflach, V., Ringh, M. V., Stark, J., Likus, W., Siemianowicz, K., Ghavami, S., Hudecki, A., Green, J. L., & Łoś, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.017 · Cited by 128
Epidermal Development in Mammals: Key Regulators, Signals from Beneath, and Stem Cells
Liu, S., Zhang, H., & Duan, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610869 · Cited by 110
“Considering the risk of insertional mutagenesis of viral vectors and spontaneous transgene reactivation, alternative gene-delivering vectors have been developed in recent years for therapeutic purposes, such as transposons [144], proteins [145], microRNAs [146], messenger RNAs [147], and so on.”
BackgroundMatsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
All Roads Lead to Induced Pluripotent Stem Cells: The Technologies of iPSC Generation
Hu, K. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0620 · Cited by 105
“The same mRNA cocktail can also reprogram human cells in a feeder-free system [87].”
BackgroundWiley, L. A., Burnight, E. R., Songstad, A. E., Drack, A. V., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.10.002 · Cited by 124
“Following these original publications, a plethora of studies focused on the use of different cell types, reprogramming factors and delivery methods were developed (Carey et al., 2009; Gonzalez et al., 2009; Jin et al., 2012; Kim et al., 2009, 2011; Tucker et al., 2013a;Warren et al., 2012; Yoshioka et al., 2013; Yu et…”
MethodHigh-efficiency cellular reprogramming with microfluidics
Luni, C., Giulitti, S., Serena, E., Ferrari, L., Zambon, A., Gagliano, O., Giobbe, G. G., Michielin, F., Knöbel, S., Bosio, A., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3832 · Cited by 107
Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications
Patel, S., Athirasala, A., Menezes, P. P., Ashwanikumar, N., Zou, T., Sahay, G., & Bertassoni, L. E. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0444 · Cited by 98
“The protocol required periodic, multiple transfections for sustained expression of reprogramming factors over the 2-week duration necessary to induce pluripotency owing to the transient nature of mRNA translation kinetics and degradation, with transgene expression peaking at 24 h.(161) While the time and laborintensiv…”
BackgroundSu, R. J., Baylink, D. J., Neises, A., Kiroyan, J. B., Meng, X., Payne, K. J., Tschudy-Seney, B., Duan, Y., Appleby, N. C., Kearns‐Jonker, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064496 · Cited by 104
Brouwer, M., Zhou, H., & Nadif Kasri, N. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9622-8 · Cited by 95
Drozd, A. M., Walczak, M. P., Piaskowski, S., Stoczyńska-Fidelus, E., Rieske, P., & Grzela, D. P. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0112-3 · Cited by 101
“charged RGD (Arg-Gly-Asp) moieties of extracellular proteins required for the maintenance of undifferentiated pluripotent cells [44–46]; especially, laminin, fibronectin, and vitronectin may promote the acquisition of pluripotent identity.”
BackgroundmRNA-Based Genetic Reprogramming
Warren, L., & Lin, C. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.009 · Cited by 87
miRNA Control of Tissue Repair and Regeneration
Sen, C. K., & Ghatak, S. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.04.001 · Cited by 94
Borgohain, M. P., Haridhasapavalan, K. K., Dey, C., Adhikari, P., & Thummer, R. P. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9861-6 · Cited by 89
Ni, P., Noh, H., Park, G.-H., Shao, Z., Guan, Y., Park, J. M., Yu, S., Park, J. S., Coyle, J. T., Weinberger, D. R., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0423-3 · Cited by 88
Methods of Generating Dielectrophoretic Force for Microfluidic Manipulation of Bioparticles
Kwizera, E. A., Sun, M., White, A. M., Lǐ, J., & He, X. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00083 · Cited by 88
Bergström, P., Agholme, L., Nazir, F. H., Satir, T. M., Toombs, J., Wellington, H., Strandberg, J., Bontell, T. O., Kvartsberg, H., Holmström, M., et al. (2016) · Scientific Reports · doi:10.1038/srep29200 · Cited by 79
Lu, H., Chai, C., Lim, T. C., Leong, M. F., Lim, J. K., Gao, S., Lim, K., & Wan, A. C. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.050 · Cited by 80
“To overcome this safety issue, xeno-free iPSC derivation using human feeder cells has recently been reported [9,10].”
BackgroundPoleganov, M. A., Eminli, S., Beissert, T., Herz, S., Moon, J.-I., Goldmann, J., Beyer, A., Heck, R., Burkhart, I., Barea Roldan, D., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.045 · Cited by 77
“…siRNA, the use of modified mRNA to reduce immunogenicity of mRNA has become a well-established reprogramming technology for human fibroblasts 16–18, 34 , 53, 54 and also enabled the generation One possible explanation for the greater overall performance using nonmodified mRNA compared with less…”
Steinle, H., Behring, A., Schlensak, C., Wendel, H. P., & Avci-Adali, M. (2017) · Stem Cells · doi:10.1002/stem.2402 · Cited by 76
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Sahin, U. (2015) · WIREs RNA · doi:10.1002/wrna.1288 · Cited by 72
Gazdhar, A., Grad, I., Tamò, L., Gugger, M., Féki, A., & Geiser, T. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt513 · Cited by 71
“New nonviral methods for generation of iPSCs have been reported recently using mRNA [49,50] and recombinant protein [51]; since the iPSC is a new and evolving technology it will take some time and effort to modify the existing protocols, but enormous strides have been already made in the field aiming to reduce the use…”
MethodFate of induced pluripotent stem cells following transplantation to murine seminiferous tubules
Durruthy-Durruthy, J., Ramathal, C. Y., Sukhwani, M., Fang, F., Cui, J., Orwig, K. E., & Pera, R. A. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu012 · Cited by 64
Strategies for Whole Lung Tissue Engineering
Calle, E. A., Ghaedi, M., Sundaram, S., Sivarapatna, A., Tseng, M. K., & Niklason, L. E. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2314261 · Cited by 66
Multisystem Lewy body disease and the other parkinsonian disorders
Langston, J. W., Schüle, B., Rees, L., Nichols, R. J., & Barlow, C. (2015) · Nature Genetics · doi:10.1038/ng.3454 · Cited by 63
Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
Rivera, T., Zhao, Y., Ni, Y., & Wang, J. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.117 · Cited by 72
“Rho-associated protein kinase (ROCK) inhibitor has been shown to increase cell survival of dissociated cells by preventing dissociation-induced apoptosis in human embryonic stem cells (Watanabe et al., 2007).”
BackgroundMurthy, N., Lee, K., Yu, P., Lingampalli, N., Kim, H. J., & Tang, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75124 · Cited by 53
Li, J., Song, W., Pan, G., & Zhou, J. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0050-z · Cited by 56
“described a simple, non-integrating strategy for reprogramming cells based on the administration of a synthetic mRNA that is modified to overcome innate anti-viral responses [38,100,101].”
BackgroundNon-Viral Generation of Marmoset Monkey iPS Cells by a Six-Factor-in-One-Vector Approach
Debowski, K., Warthemann, R., Lentes, J., Salinas, G., Dressel, R., Langenstroth, D., Gromoll, J., Sasaki, E., & Behr, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118424 · Cited by 51
Durruthy-Durruthy, J., Briggs, S. F., Awe, J., Ramathal, C. Y., Karumbayaram, S., Lee, P. C., Heidmann, J. D., Clark, A., Karakikes, I., Loh, K. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094231 · Cited by 52
“Importantly we used the native versions of the five transcription factors as opposed to Warren et al., 2012 where six reprogramming factors (addition of NANOG) and a modified version of OCT3/4 [16] (addition of an N-terminal transactivation MyoD domain) were used.”
MethodDifferentiation of Human Induced Pluripotent Stem Cells into a Keratinocyte Lineage
Kogut, I., Roop, D. R., & Bilousova, G. (2013) · Methods in molecular biology · doi:10.1007/7651_2013_64 · Cited by 61
“The provided protocol is optimized for iPSCs generated with an integration-free modified mRNA-based reprogramming approach (21, 22).”
MethodUrine-derived cells provide a readily accessible cell type for feeder-free mRNA reprogramming
Gaignerie, A., Lefort, N., Rousselle, M., Forest, V. F., Flippe, L., François-Campion, V., Girardeau, A., Caillaud, A., Chariau, C., Francheteau, Q., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32645-2 · Cited by 59
Heng, B. C., Heinimann, K., Miny, P., Iezzi, G., Glatz, K., Scherberich, A., Zulewski, H., & Fussenegger, M. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2013.02.004 · Cited by 49
Feeder‐Free Reprogramming of Human Fibroblasts with Messenger RNA
Warren, L. A., & Wang, J. (2013) · Current Protocols in Stem Cell Biology · doi:10.1002/9780470151808.sc04a06s27 · Cited by 43
Transcription factors: Time to deliver
Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.004 · Cited by 45
Recent technological updates and clinical applications of induced pluripotent stem cells
Diecke, S., Jung, S. M., Lee, J., & Ju, J. H. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.5.547 · Cited by 51
“The recent optimization of established mRNA reprogramming factors has addressed some of the aforementioned caveats, allowing the production of footprint-free iPSCs from human fibroblasts without the use of feeder cells or other possibly xeno-contaminated reagents [39].”
BackgroundInduced Pluripotent Stem Cells in Disease Modeling and Gene Identification
Kumar, S., Blangero, J., & Curran, J. E. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7471-9_2 · Cited by 45
“[66] reported increased RNA reprogramming efficiencies and accelerated colony emergence by fusing Oct4 to a heterologous transactivation domain.”
BackgroundMeyer, S., Wörsdörfer, P., Günther, K., Thier, M. C., & Edenhofer, F. (2015) · Journal of Visualized Experiments · doi:10.3791/52831 · Cited by 39
Few Single Nucleotide Variations in Exomes of Human Cord Blood Induced Pluripotent Stem Cells
Su, R.-J., Yang, Y., Neises, A., Payne, K. J., Wang, J., Viswanathan, K., Wakeland, E. K., Fang, X., & Zhang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059908 · Cited by 39
“Technological breakthroughs have made it possible to generate integration-free iPSCs with modified mRNAs [4,5], non-integrating Sendai virus [6,7,8,9,10] or oriP/EBNA1-based episomal vectors [11,12,13,14,15,16,17,18,19] and other methods, which brings iPSC-based therapy one step closer to clinical application.”
Patient-derived induced pluripotent stem cells for modelling genetic retinal dystrophies
Foltz, L. P., & Clegg, D. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.09.002 · Cited by 39
Badieyan, Z. S., & Evans, T. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0259 · Cited by 38
Steinle, H., Weber, M., Behring, A., Mau-Holzmann, U. A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2019) · Stem Cells International · doi:10.1155/2019/7641767 · Cited by 39
“Thus, to prevent interferon-response induced cell death, the reprogramming medium needs to contain the interferon inhibitor B18R derived from vaccinia virus [6, 20, 21].”
BackgroundInfluentialGeneration of Mouse and Human Induced Pluripotent Stem Cells (iPSC) from Primary Somatic Cells
Lorenzo, I. M., Fleischer, A., & Bachiller, D. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-012-9412-5 · Cited by 37
“Depending on the species of the donor and the type of starting primary cell, the difficulties and time involved in producing iPSC from somatic cells vary [11, 38].”
Mormone, E., D'Sousa, S., Alexeeva, V., Bederson, M. M., & Germano, I. M. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0151 · Cited by 39
Lam, I., Ndayisaba, A., Lewis, A. J., Fu, Y., Sagredo, G. T., Kuzkina, A., Zaccagnini, L., Celikag, M., Sandoe, J., Sanz, R. L., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.06.002 · Cited by 38
Generation of human induced pluripotent stem cells using non-synthetic mRNA
Rohani, L., Fabian, C., Holland, H., Naaldijk, Y., Dressel, R., Löffler-Wirth, H., Binder, H., Arnold, A., & Stolzing, A. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.03.008 · Cited by 35
Preskey, D., Allison, T. F., Jones, M., Mamchaoui, K., & Unger, C. A. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.102 · Cited by 35
Bioengineering of Articular Cartilage: Past, Present and Future
Ye, K., Felimban, R. I., Moulton, S. E., Wallace, G. G., Bella, C. D., Traianedes, K., Choong, P., & Myers, D. E. (2013) · Regenerative Medicine · doi:10.2217/rme.13.28 · Cited by 40
mRNA Transfection of Mouse and Human Neural Stem Cell Cultures
McLenachan, S., Zhang, D., Palomo, A. B. A., Edel, M. J., & Chen, F. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083596 · Cited by 30
Netsrithong, R., García-Pérez, L., & Themeli, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325209 · Cited by 44
“Recombinant proteins (88), DNA plasmids (23, 89), Sendai virus (90 – 93) or mRNA-based methods (25, 94) are all non-integrative technologies used to transiently express transcription factors needed to induce cell reprogramming.”
MethodMehta, A. K., Verma, V., Nandihalli, M., Ramachandra, C. J. A., Sequiera, G. L., Sudibyo, Y., Chung, Y., Sun, W. Y., & SHIM, W. S. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103485 · Cited by 36
Wang, A. Y. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158148 · Cited by 35
Induced Pluripotent Stem Cells in Dermatology: Potentials, Advances, and Limitations
Bilousova, G., & Roop, D. R. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015164 · Cited by 36
“This approach has been shown to reprogram a variety of cell lines with the efficiency that surpasses that of the other integration-free protocols (Warren et al. 2010, 2012).”
BackgroundOvercoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316929 · Cited by 35
“As opposed to reprogramming by episomal DNA vectors, mRNA-based reprogramming relies on sequential introductions of mRNA sequences encoding for reprogramming inducing transcription factors [37].”
BackgroundGeneration of transgene-free porcine intermediate type induced pluripotent stem cells
Li, D., Secher, J. B., Hyttel, P., Ivask, M., Kolko, M., Hall, V. J., & Freude, K. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1548790 · Cited by 30
Meraviglia, V., Zanon, A., Lavdas, A. Α., Schwienbacher, C., Silipigni, R., Segni, M. D., Chen, H.-S. V., Pramstaller, P. P., Hicks, A. A., & Rossini, A. (2015) · Journal of Visualized Experiments · doi:10.3791/52885 · Cited by 32
Cellular models for human cardiomyopathy: What is the best option?
Jiménez-Téllez, N., & Greenway, S. C. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i10.221 · Cited by 29
Dey, C., Raina, K., Haridhasapavalan, K. K., Thool, M., Sundaravadivelu, P. K., Adhikari, P., Gogoi, R., & Thummer, R. P. (2021) · Recent Advances in iPSC Technology · doi:10.1016/b978-0-12-822231-7.00011-4 · Cited by 23
Tan, L. S., Chen, J. T., Lim, L. Y., & Teo, A. K. K. (2022) · Cell Proliferation · doi:10.1111/cpr.13232 · Cited by 25
Induced Pluripotent Stem Cells and Periodontal Regeneration
Du, M., Duan, X., & Yang, P. (2015) · Current Oral Health Reports · doi:10.1007/s40496-015-0065-8 · Cited by 26
Guerreiro, S. R., & Maciel, P. (2023) · Cells · doi:10.3390/cells12040538 · Cited by 21
Mishra, S., Kaçin, E., Stamatiadis, P., Franck, S., der Jeught, M. V., Mertes, H., Pennings, G., Sutter, P. D., Sermon, K., Heindryckx, B., et al. (2018) · Molecular Human Reproduction · doi:10.1093/molehr/gay007 · Cited by 18
“The transfection of mRNA encoding reprogramming factors is probably one of the safest techniques and has been shown to efficiently generate iPSC (Warren et al., 2010, 2012; Yakubov et al., 2010; Kehler et al., 2017).”
Bekhite, M. M., & Schulze, P. C. (2021) · Cells · doi:10.3390/cells10123483 · Cited by 25
“To generate iPSCs that are free from viral contamination, and also non-integrative systems, considerable progress has been made by transfecting DNA into cells using liposomes or electroporation, such as plasmids, episomal plasmids [57–62], minicircle DNA [63,64], removable piggyBac transposon followed by Cre transfect…”
MethodRNA-Based Strategies for Cell Reprogramming toward Pluripotency
Bailly, A., Milhavet, O., & Lemaître, J.-M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020317 · Cited by 20
Jung, L., Tropel, P., Moal, Y., Teletin, M., Jeandidier, É., Gayon, R., Himmelspach, C., Bello, F., André, C., Tosch, A., et al. (2014) · Molecular Human Reproduction · doi:10.1093/molehr/gau012 · Cited by 19
“Nevertheless, in mRNA-mediated iPS generation, NANOG confirms its facilitating role in human (Warren et al., 2012).”
BackgroundLee, S. J., Kang, K., Kim, J.-H., Lee, B., Jung, J., Park, Y., Hong, S., & Kim, B. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0188 · Cited by 14
“However, when combined with the expression of OSKM, many of these modulators do not enhance the overall reprogramming efficiency significantly, raising concerns regarding the convenience of these reprogramming procedures [3–5].”
Therapeutic applications of cell engineering using mRNA technology
He, Y., Johnston, A. P. R., & Pouton, C. W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.012 · Cited by 14
Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences
Rhoads, R. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3625-0_1 · Cited by 13
Ndayisaba, A., Pitaro, A. T., Willett, A. S., Jones, K. A., de Gusmão, C. M., Olsen, A. L., Kim, J., Rissanen, E., Woods, J. K., Srinivasan, S. R., et al. (2022) · The Cerebellum · doi:10.1007/s12311-022-01471-8 · Cited by 11
Ni, P., Zhou, C., Liang, S., Jiang, Y., Liu, D., Shao, Z., Noh, H., Zhao, L., Yang, T., Zhang, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202300455 · Cited by 15
Augustyniak, J., Zychowicz, M., Podobińska, M., Bárta, T., & Bużańska, L. (2014) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2014-2000 · Cited by 14
Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine
Inagaki, M. (2023) · Journal of Developmental Biology · doi:10.3390/jdb12010001 · Cited by 13
The occurrence and development of induced pluripotent stem cells
Chen, Y., Li, M., & Wu, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1389558 · Cited by 18
“Compared with the other methods mentioned above, mRNA-based reprogramming is faster and more ef fi cient and has a lower risk of mutation (Warren et al., 2010; Warren et al., 2012).”
ResultKim, M., Hwang, S., Yoon, J. D., Jeong, Y. W., Kim, E., & Hyun, S. (2020) · Animals · doi:10.3390/ani10101848 · Cited by 10
“Recently, RNA-based iPSC approaches using four individual reprogramming-factor mRNAs generated by IVT were noted [41,58,59].”
BackgroundMigratory cortical interneuron-specific transcriptome abnormalities in schizophrenia
Park, J. M., Liu, D., Park, G.-H., Noh, H., Ni, P., Yin, C., Huang, W., & Chung, S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.054 · Cited by 9
Reprogramming cells with synthetic proteins
Jauch, R., Yang, X., & Malik, V. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.145433 · Cited by 7
Drouin‐Ouellet, J. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.26 · Cited by 9
Sharma, M., Kumar, R., Sharma, S., Thomas, B. E., Kapatia, G., Singh, G., Bal, A., Ram, J., Bhasin, M., Guptasarma, P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/679928 · Cited by 13
“…to 1% with integrating viruses, and to 0.001% with the non-integrating Sendai virus, adenovirus, plasmids and direct protein delivery (Zhou et al., 2013; Iseki et al., 2016; Bar-Nur et al., 2014; Buganim et al., 2014; Hou et al., 2013; Carey et al., 2011; Warren et al., 2010; Warren et al., 2012).”
BackgroundMethodInfluential
Metadata
- Authors
- Warren, L., Ni, Y., Wang, J., & Guo, X.
- Affiliations
- Allele Biotechnology (United States) (US)
- Nanjing Maternity and Child Health Care Hospital (CN)
- Scintillon Institute (US)
- Corresponding author
- Wang, Jiwu
- Guo, Xirong
- Venue
- Scientific Reports
- Published
- 2012-09-14
- Volume
- 2
- Issue
- 1
- Pages
- 657-657
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3442198
- OpenAlex
- W2003316226
- Cited by
- 154
- References
- 46
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 9 · 2020: 4 · 2019: 13 · 2018: 18 · 2017: 4 · 2016: 10 · 2015: 20 · 2014: 31 · 2013: 14 · 2012: 3
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81100618, 30973231)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- induced pluripotent stem cells, feeder-free culture, somatic cell reprogramming
- MeSH terms
- Nanog Homeobox Protein, Cell Survival, Cells, Cultured, Humans, RNA, Messenger, Herpes Simplex Virus Protein Vmw65, MyoD Protein, Homeodomain Proteins, Coculture Techniques, Cell Shape, Cell Proliferation, Octamer Transcription Factor-3, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.